AgomAb Therapeutics NV financial statements
AgomAb Therapeutics NV's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
FY2025
| Revenue | EUR 0 | EODHD |
| Net income | −EUR 62.55M | EODHD |
| Cash and equivalents | EUR 86.42M | EODHD |
| Total debt | EUR 1.25M | EODHD |
AgomAb Therapeutics NV financials on 6ix · AgomAb Therapeutics NV on 6ix